Evaluative Clinical Sciences

Administrative Assistant: Sarah Persaud
Phone: 416-480-4974
Email: sarah.persaud@sunnybrook.ca

Education:

• HBSc, 2010, Laboratory Medicine and Pathobiology, University of Toronto, Canada
• MD, 2014, Doctor of Medicine, University of Toronto, Canada
• MPH, 2021, Master of Public Health in Quantitative Methods, Harvard T.H. Chan School of Public Health, USA

Appointments and Affiliations:

• Assistant Professor, Department of Radiation Oncology, University of Toronto
• Associate Scientist, Evaluative Clinical Sciences, Sunnybrook Research Institute
• Radiation Oncologist, Sunnybrook Odette Cancer Centre

Research Foci:

• Adaptive radiotherapy for CNS malignancies
• SRS and SBRT for oligometastases
• SBRT for spine tumours
• Stereotactic radiotherapy and re-irradiation for breast malignancies

Research Summary:

Dr. Chen is a researcher focusing on applying quantitative modelling methods to important clinical questions, allowing subtle, underlying trends to be seen and used to guide subsequent clinical decisions. He applies these methods to determine factors that can predict patient outcomes following stereotactic body radiation therapy for spine tumours and oligometastatic tumours elsewhere in the body. Dr. Chen also has an interest in developing and applying new radiation technologies, such as adaptive radiotherapy and stereotactic radiosurgery/stereotactic body radiation therapy for, to new clinical indications in the CNS and breast.

Selected Publications:

See current publications list at PubMed.

1. Chen H, van Sornsen de Koste JR, Bohoudi O, Bruynzeel A, Slotman BJ, Lagerwaard FJ, Palacios M, Senan S. Impact of Daily Plan Adaptation on Organ-At-Risk Normal Tissue Complication Probability for Adrenal Lesions undergoing Stereotactic Ablative Radiation Therapy. Radiotherapy and Oncology. 2021 July 21;163:14-20.
2. Chen H, Poon I, Atenafu EG, Badellino S, Biswas T, Dagan R, Erler D, Foote M, Redmond KJ, Ricardi U, Sahgal A, Louie AV. Development of Prognostic Model for Overall Survival in Patients with Extracranial Oligometastatic Disease Treated with Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021 December 8: Epub ahead of print. Available from: https://www.sciencedirect.com/science/article/pii/S0360301621032363
3. Chen H, Badellino S, Biswas T, Dagan R, Erler D, Foote M, Poon I, Redmond KJ, Ricardi U, Sahgal A, Louie AV. Conditional survival of extracranial oligometastatic patients treated with stereotactic body radiation therapy (SBRT): an international consortium study. Int J Radiat Oncol Biol Phys. 2022: Epub ahead of print. Available from: https://pubmed.ncbi.nlm.nih.gov/35753554/.
4. Chen H, Laba J, Zayed S, Boldt RG, Palma DA, Louie AV. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Cancer: A Systematic Review. Journal of Thoracic Oncology. 2019 May 7; S1556-0864(19)30315-6. Available from: https://pubmed.ncbi.nlm.nih.gov/31075543/.
5. Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, Louie AV. Stereotactic Ablative Radiotherapy Versus Surgery in Early Lung Cancer: A Meta-Analysis of Propensity Score Studies. Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):186-194.

Related News and Stories:

• University of Toronto faculty profile